Actively Recruiting
mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria
Led by New York University · Updated on 2026-05-13
900
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Large knowledge gaps remain regarding strategies to promote the adoption of hydroxyurea (HU), particularly in sub-Saharan African countries including Nigeria, where more than 75% of annual sickle cell anemia births occur. The vast majority of people with SCD in Africa do not receive evidenced-based health care (e.g., newborn screening, health education, prophylaxis for infection, optimal nutrition and hydration, blood transfusion, transcranial Doppler screening, and HU therapy), despite its effectiveness in reducing SCD-related adverse outcomes and mortality. The use of HU in SSA is \<1% among SCD patients. The investigators' preliminary findings indicate that provider-level barriers are significant and must be addressed to improve HU adoption. To address HU adoption, the investigators will use the NIH-funded study (e.g., Realizing Effectiveness Across Continents with Hydroxyurea (REACH) Clinical Trial (NCT01966731)) that developed an evidence-informed, clinical, practical, and easy-to-follow algorithm to 1) Screen patients for sickle cell disease (SCD), 2) Initiate HU treatment, and 3) Maintain HU dosage over time (SIM) for the improved management of SCD as our intervention. The Nigerian government released guidelines supporting the SIM intervention for HU adoption for improved SCD management, and HU is on the list of essential medicines for Nigeria. The investigators' implementation strategy for improving SCD management in Nigeria uses a practical and replicable evidence-based task-sharing strategy, TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH), adopted from the TAsk-Strengthening Strategy for Hypertension control (TASSH) trials in Ghana and Nigeria containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management. Using a sequential exploratory mixed-methods study design, the investigators will conduct this study using the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework in four sequential phases to assess the effectiveness of SIM adoption by providers in the context of the TASSH TCP implementation strategy in Nigeria.
CONDITIONS
Official Title
mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria
Who Can Participate
Eligibility Criteria
You may qualify if you...
- SCD patients 18 years or older who have provided consent
- Pediatric SCD patients aged 12 months to 17 years with an accompanying guardian who have provided informed consent or assent
- Registration in the electronic medical records (EMR) database with clinical charts and receiving care at local clinical sites or health facilities
- Patients not currently on hydroxyurea (HU) therapy
- Hb Genotype includes SCD-SS, SCD-Sβ0 thal, SCD-SOArab; on a case-by-case basis, severely affected SCD-SC patients may be offered HU under a modified protocol
You will not qualify if you...
- Any SCD patient not registered in the EMR database or without informed consent or assent
- Patients physically unable to participate in study activities
- SCD patients currently on hydroxyurea (HU) therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Of Abuja Teaching Hospital
Abuja, Nigeria
Actively Recruiting
Research Team
E
Emmanuel Peprah, PhD
CONTACT
O
Obiageli Nnodu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here